open new horizons for stem cell therapy
Stem cells are receiving a lot of attention for their roles in immunomodulation, inflammation control, and regeneration, and several companies and research institutes are promoting the commercialization of stem cell therapeutics. However, there are currently limitations in the development of stem cell therapies, including their weak efficacy and heterogenic characteristics. Continued exploration is needed to address these challenges and improve therapeutic efficacy.
To standardize the therapeutic capacity of stem cell therapies, CELLnLIFE Inc. has developed the “Cell-Matrix Suspension technique” and "S-I-S culture platform," which can minimize the genetic heterogeneity of stem cells and maximize functional gene expression to allow optimal stem cell treatment with excellent functionality and homogeneity.
“Cell-Matrix Suspension” technique, a unique method for isolation of hUC-MSCs
→ High yield, homogenous appearance, primitive properties
S-I-S Culture Platform
Donor/tissue selection and biomarker screening for the development of functionally enhanced stem cell therapeutics
Cell-to-cell interaction for gene expression enhancement and homogenization
Increase expression of effective factors specific for disease treatment through the selection and application of stimulating factors
IntenCell®, maximize therapeutic efficacy
Maximize cell functions to show immediate therapeutic effect after administration
Maintain active treatment efficacy for 1 ~ 4 weeks after administration
Apply to diseases related to immune regulation, and tissue regeneration